The corresponding placebo consist of the 25 mm phosphate buffer solution with 2 µg of vitamin b2 added for colouring purposes only
Sponsors
Ribocure Pharmaceuticals AB
Conditions
Coronary artery diseaseStable Coronary Artery DiseaseVenous Thromboembolismnon-valvular atrial fibrillation
Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Repeated Subcutaneously Administered RBD4059 in Participants with Stable Coronary Artery Disease
Active, not recruitingCTIS2023-510370-14-00
Start: 2024-08-28Target: 30Updated: 2025-12-12
A randomised active-controlled trial to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation
Not yet recruitingCTIS2026-525417-31-00
Target: 20Updated: 2026-07-24
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial to Evaluate Safety, and Pharmacodynamics of Repeated Subcutaneously Administered RBD1119 in Participants with CAD
Not yet recruitingCTIS2026-525901-10-00
Target: 60Updated: 2026-08-18
Randomized, Double blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants with Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)
Not yet recruitingCTIS2026-525479-15-00
Target: 44Updated: 2026-09-04